Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.SCOLR Pharma, a specialty pharmaceutical company, has named Carl Johnson as the new chairman of its board of directors.
Subscribe to our email newsletter
Most recently, Johnson worked as the president and CEO of Matrixx Initiatives.
Prior to that, Johnson also has served as vice president, Commercial Development, for Perrigo Company and before that was with Johnson & Johnson in both the consumer and professional healthcare products divisions.
Taglich outgoing chairman SCOLR said that in the short time that he has been a member of the board, Carl’s active involvement with management, and his industry expertise have greatly impressed the board.
SCOLR Pharma is focused on applying its formulation expertise and patented CDT platforms to develop novel prescription pharmaceutical, over-the-counter (OTC), and nutritional products.
SCOLR Pharma said that its CDT drug delivery platforms are based on multiple issued and pending patents and other intellectual property for the programmed release or enhanced performance of active pharmaceutical ingredients and nutritional products.